The Company

Avilex Pharma is a spin out from the University of Copenhagen, founded by Professor Kristian Strømgaard and Assis. Prof. Anders Bach of the Department of Drug Design and Pharmacology, with investment from Novo Seeds (part of Novo A/S) and Wellcome Trust.

Avilex won the  ‘The Copenhagen Spin-outs Award for most promising company/project 2012-13
and has been nominated for ‘Falling Walls Science Start-Up of the Year 2013

 

BOARD/MANAGEMENT

Avilex_Mark_Treherne

CEO

Mark Treherne

PhD

Avilex_Kristian_Strømgaard

CSO

Kristian Strømgaard

PhD, Professor

Avilex_Mikael_Thomsen

CDO

Mikael Thomsen

PhD

Avilex_Anders_Bach

CONSULTANT

Anders Bach

PhD, Assis. Prof.

BOARD OF DIRECTORS

Avilex_Raymond_Hill

Raymond Hill

PhD, Chairman of the board

Emmanuelle-Coutanceau

Emmanuelle Coutanceau

PhD, Investment Director, Novo Seeds

New paradigm in clinical stroke studies

Clinical studies of ischemic stroke are currently undergoing exciting changes, in particular with the ability of early onset treatment. Recently seminal examples of this have been published including the PHANTOM-S, MR CLEAN, and FAST-MAG studies. This provides an exciting perspective for new treatment of ischemic stroke.

Getting chemistry and biology to communicate

Copenhagen Spin-outs features an in-depth profile of Avilex Pharma and its CEO/CSO Kristian Strømgaard.

Read More

© Copyright 2017 Avilex Pharma. All rights reserved.
Avilex Pharma, Ole Maaløes Vej 3, 2200 Copenhagen, DK